Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

HOOKIPA PHARMA INC.

(HOOK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

HOOKIPA Pharma to Participate in Upcoming Stifel 2021 Virtual Healthcare Conference

11/12/2021 | 07:02am EST

NEW YORK and VIENNA, Austria, Nov. 12, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA’s management team will participate in the Stifel 2021 Virtual Healthcare Conference that will be held November 15th – 17, 2021.

Corporate Presentation: Monday, November 15, 2021 at 10:40 AM EST
Webcast Link: https://wsw.com/webcast/stifel58/hook/2101140

The webcast of the presentation will be available within the Investors & Media section of HOOKIPA’s website at https://ir.hookipapharma.com/events. An archived replay will be accessible for 30 days following the event.

About HOOKIPA

HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies that mobilize and amplify targeted T cells to address unmet needs in cancer.

The company is leveraging its proprietary, versatile platform to engineer a broad pipeline of differentiated arenaviral therapeutics. These novel immunotherapies induce robust antigen-specific killer T cells to a broad range of self and non-self antigens, including viral antigens, tumor-associated antigens and neoantigens. HOOKIPA’s platform technology uses replicating viral vectors based on the target cancer, with the potential to induce killer T cell response levels previously not achieved by other immunotherapy approaches.

HOOKIPA’s pipeline includes wholly-owned investigational arenaviral immunotherapeutics targeting HPV16+ cancers, prostate cancer, KRAS-mutated cancers (including colorectal, pancreatic and lung), and other undisclosed projects. In addition, the company aims to develop functional cures of HBV and HIV in collaboration with Gilead.

Find out more about HOOKIPA online at www.hookipapharma.com.

Forward Looking Statements

Certain statements set forth in this press release constitute “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by terms such as “believes,” “expects,” “plans,” “potential,” “would” or similar expressions and the negative of those terms. Such forward-looking statements involve substantial risks and uncertainties that could cause HOOKIPA’s research and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including HOOKIPA’s programs’ early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, HOOKIPA’s ability to successfully establish, protect and defend its intellectual property, risks relating to business interruptions resulting from the coronavirus (COVID-19) disease outbreak or similar public health crises, the impact of COVID-19 on the enrollment of patients and timing of clinical results for HB-101 and other programs, and other matters that could affect the sufficiency of existing cash to fund operations and HOOKIPA’s ability to achieve the milestones under the agreement with Gilead. HOOKIPA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see HOOKIPA’s quarterly report on Form 10-Q for the quarter ended September 30, 2021 which is available on the Securities and Exchange Commission’s website at www.sec.gov and HOOKIPA’s website at www.hookipapharma.com.

Investors and others should note that we announce material financial information to our investors using our investor relations website (https://ir.hookipapharma.com/), SEC filings, press releases, public conference calls and webcasts. We use these channels, as well as social media, to communicate with our members and the public about our company, our services and other issues. It is possible that the information we post on social media could be deemed to be material information. Therefore, we encourage investors, the media, and others interested in our company to review the information we post on the U.S. social media channels listed on our investor relations website.

For further information, please contact: 
  
MediaInvestors
Astrid van ErvenMatt Beck
Senior Manager - CommunicationsExecutive Director - Investor Relations
astrid.vanerven@hookipapharma.commatthew.beck@hookipapharma.com
  
Media enquiries 
Instinctif Partners 
hookipa@instinctif.com 
+44 (0)20 7457 2020 

Primary Logo

Source: HOOKIPA Pharma Inc.

2021 GlobeNewswire, Inc., source Press Releases

All news about HOOKIPA PHARMA INC.
01/19HOOKIPA Announces First Patient Enrolled in Phase 2 Trial Evaluating HB-200 and Pembrol..
AQ
01/18Hookipa Pharma's Two Cancer Therapies Get FDA Fast-Track Designation; Shares Rise
MT
01/18HOOKIPA Announces First Patient Enrolled in Phase 2 Trial Evaluating HB-200 and Pembrol..
AQ
01/18HOOKIPA Pharma Inc. Announces First Patient Enrolled in Phase 2 Trial Evaluating HB-200..
CI
01/04HOOKIPA Pharma to Present at the H.C. Wainwright BioConnect Conference
AQ
2021Kempen Downgrades HOOKIPA Pharma to Neutral From Buy, Adjusts Price Target to $2.60 Fro..
MT
2021HOOKIPA Pharma to Participate in the JMP Securities Hematology and Oncology Summit
AQ
2021HOOKIPA Pharma to Participate in the JMP Securities Hematology and Oncology Summit
AQ
2021HOOKIPA Pharma to Participate in Upcoming Stifel 2021 Virtual Healthcare Conference
AQ
2021Morgan Stanley Downgrades HOOKIPA Pharma to Equal-Weight From Overweight; Price Target ..
MT
More news
Analyst Recommendations on HOOKIPA PHARMA INC.
More recommendations
Financials (USD)
Sales 2021 18,7 M - -
Net income 2021 -76,1 M - -
Net cash 2021 89,9 M - -
P/E ratio 2021 -0,63x
Yield 2021 -
Capitalization 43,7 M 43,7 M -
EV / Sales 2021 -2,47x
EV / Sales 2022 -4,05x
Nbr of Employees 123
Free-Float -
Chart HOOKIPA PHARMA INC.
Duration : Period :
HOOKIPA Pharma Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HOOKIPA PHARMA INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 1,46 $
Average target price 13,71 $
Spread / Average Target 839%
EPS Revisions
Managers and Directors
J÷rn Aldag Chief Executive Officer & Director
Thomas Lingelbach President
Reinhard Kandera Chief Financial Officer
Jan G. J. van de Winkel Chairman
Igor Matushansky Chief Medical Officer & Global Head-Research
Sector and Competitors
1st jan.Capi. (M$)
HOOKIPA PHARMA INC.-35.62%45
JOHNSON & JOHNSON-2.01%441 302
ROCHE HOLDING AG-8.68%304 745
PFIZER, INC.-11.02%294 900
ABBVIE INC.-1.71%235 287
ELI LILLY AND COMPANY-13.31%217 093